https://t.co/OlvGLWVKbs

Slight correction: one of our amazing recruiting teams managed to inform and recruit a patient very last minute, so we actually finished at 119 patients 😊🤩

That's a wrap 🎉 APHRODITE has finished recruitment: 118 early stage rectal cancer patients randomised 2:1 between 62Gy and 50.4Gy #radonc We will have primary endpoint data (cCR rates @ 6 months) next summer 🌞 Many, many thanks to all trial sites, PIs, and patients 😍

Also in our #YorkshireDay series. The @aphrodite_trial, spearheaded by @cancerphysicist aims to find out if a higher radiotherapy dose will give greater benefit to patients with #bowelcancer @LeedsCTRU @LTHRadiotherapy

We’ve recruited 100 patients! 🎉🎉🎉 Many congratulations to Dr Muirhead and team at @OUHospitals for getting us to this lovely round number - only a few to go now 😳 #radonc #rectalcancer

Excellent presentation demonstrating highly quality assured radiotherapy in the ⁦@yorkshirecancer⁩ funded APHRODITE organ preservation rectal cancer trial including boost delivery ⁦@LeedsCTRU⁩ ⁦@cancerphysicist⁩ ⁦@UniversityLeeds⁩ ⁦@LeedsHospitals⁩

Dose planning results from our @aphrodite_trial trial presented by Debra Howard @RTTQA_UK 😊 The trial use a novel mesorectal volume with SIB, implemented in a multicentre setting. Luckily, that’s been feasible, with almost identical OAR doses in the two arms #ESTRO24 #radonc

We're on 90 patients! 🎉 Getting close now ... @yorkshirecancer @LeedsRTresearch

Happy New Year! Yesterday, colleagues @TheChristieNHS recruited patient 83 (out of 104) 🎉 🎉 And last week @yorkshirecancer approved a £176k extension to our trial grant, ensuring that we can complete recruitment and FU as planned for all patients 🥳🥳🥳 @LeedsCTRU #radonc

The ⁦@UniversityLeeds⁩ ⁦@aphrodite_trial⁩ trial is testing a smarter kinder radiotherapy treatment in early rectal cancer. Funded by ⁦@yorkshirecancer⁩ and run by ⁦@LeedsCTRU⁩ it is benefiting patients on both sides of the Pennines.

It's fantastic to see research funded by the charity making a difference to lives across the country 💙

More great media coverage for APHRODITE today! The trial is a testament to the close ongoing collaboration between @LeedsCTRU and @LeedsRTresearch - and would not have happened without essential funding and support from @yorkshirecancer @UniversityLeeds https://t.co/GGPYAHHFwU

Great to see a patient from the @aphrodite_trial bravely sharing their story. It is a real pleasure to provide the quality assurance for this trial and we are delighted that 75/104 patients have now been recruited. Well done team!

We hope that many more patients with rectal cancer, like Tom, can benefit from radiotherapy in the future, and avoid surgery and a stoma. 75 out of 104 patients recruited - not far to go now! #radonc #rectalcancer

Brilliant to see @Independent highlighting the APHRODITE trial - and to read Tom Critchley's story as a patient on the trial. Tom, thank you so much for helping other cancer patients by contributing to clinical research 😍 https://t.co/JVqzD8cpIw

It’s such a great feeling when your trial finally hits its recruitment groove. Never easy but always worth the effort @cancerphysicist 👍👏💪

July was our best month yet for recruitment! We recruited ✨7 patients✨ across our 11 trial sites, brining us to a total of 63 patients (out of 104 planned) A special shout-out to @TheChristieNHS, where @ClaireLArthur & colleagues recruited 3 patients! #rectalcancer #radonc

Thanks to everyone who came to discuss our working paper on the interim @aphrodite_trial patient preference results! We look at the trade-offs patients having radiotherapy for rectal cancer make between cure/side effects - relevant for clinical dose-escalation studies #hesg2023

Breaking my holiday (semi-)silence for these exciting (preliminary) results from the @aphrodite_trial patient preference sub-study - exploring patient treatment preferences in the setting of non-operative management of #rectalcancer #radonc

I'm going to be sliding into your SMDMs this morning, presenting interim results from the @aphrodite_trial patient preference project @socmdm #esmdm23

Excellent to see our @EFOMP_org work on the involvement of #medphys in clinical trials expertly presented by @NatLAbbott on the #ESTRO23 stage (And I definitely appreciated the @aphrodite_trial mention!)